Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response

Current Medical Research and Opinion

Volumn 26, Issue 7, 2010, Pages 1733-1743

  Zeuzem, Stefan ^a   Poordad, Fred ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Chronic disease; Hepatitis C; Peginterferon; Ribavirin; Therapeutics

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDLINE; POPULATION; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RNA VIRUS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ALGORITHM; DRUG COMBINATION; DRUG EFFECTS; EVALUATION STUDY; HEPATITIS C, CHRONIC; PERSONALIZED MEDICINE; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ALGORITHMS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL LOAD;

EID: 77953607625     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.487038     Document Type: Review

References (38)

1. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374
2. Poynard T, Yuen M-F, Ratziu V, et al. Viral hepatitis C. Lancet 2003;362: 2095-2100
3. Bruno R, Sacchi P, Maiocchi L, et al. Host factors affecting the outcome of treatment of hepatitis C. Rev Gastroenterol Disord 2004;4:S3-7
4. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008;6:864-876
5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
6. Zeuzem S, Fried MW, Reddy KR, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®). Hepatology 2006;44: 267A
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
9. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652
10. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-433
11. Shiffman ML, Mansbach H, Hammond J, et al. The effect of complete and partial response at week 12 on sustained virologic response: results from controlled trials in naive HCV genotype 1 patients treated with pegylated interferon and ribavirin. Hepatology 2007;46:824A
12. McHutchison JG, LawitzEJ, Shiffman ML, etal. Peginterferon alfa-2b or alfa-2a with ribavarin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593
13. Martinot-Peignoux M, Maylin S, Ripault M-P, etal. Assessment of virological response at week 4 and at week 12 optimizes prediction of treatment outcomes in patients with chronic hepatitis C treated with peginterferon alfa-2b plus ribavirin. Poster presented at 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, November 2-6,2007
14. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960
15. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103
16. Craxi A, Zuckerman E, Koutsounas S, et al. PREDICT study final results: efficacy and safety of a 24-wk regimen of peginterferon alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C virus (HCV) genotype 1 (G1) with low viral load who achieve rapid viral response. Presented at 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 30-November 3, 2009
17. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884-1893
18. PegIntron. Summary of Product Characteristics. Bruxelles, Belgium: SP Europe, 2008
19. Ferenci P, Laferl H, ScherzerTM, etal. Peginterferon alfa-2aand ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458
20. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50
21. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C type 1 and 4 patients with slow virological response. Gastroenterology 2010;138:503-12.e1
22. Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-377
23. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352: 2609-2617
24. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-1265
25. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527
26. Yu M-L, Dai C-Y, Huang J-F, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559
27. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-1845
28. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42
29. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357: 124-134
30. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginter-feron alfa-2b\+ weight-based ribavirin in European and Asian genotype 2 and 3 chronic hepatitis C patients (REDD 2/3 Trial). J Hepatol 2009;50:S59
31. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009;49:358-363
32. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097
33. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-460
34. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow respon-ders. Hepatology 2007;46:1688-1694
35. Buti M, Lurie Y, Zakharova NG, et al. Extended treatment duration in chronic hepatitis C genotype 1-infected slow responders: final results of the SUCCESS study. J Hepatol 2009;50:S58
36. PegIntron (Peginterferon Alfa-2b) Injection. Kenilworth, NJ: Schering Corporation, 2009
37. Pegasys (Peginterferon Alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc., 2004
38. Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with pegin-terferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? Hepatology 2007;46:S6